Denosumab Boosts Survival, Not Just Bones, in Breast CancerDenosumab Boosts Survival, Not Just Bones, in Breast Cancer

New results from the ABSCG-18 trial fuel the argument for bone-strengthening cancer therapies. Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Related Links:

Publication date: Available online 19 March 2019Source: European Journal of Integrative MedicineAuthor(s): Shiao Li Oei, Anja Thronicke, Matthias Kröz, Cornelia Herbstreit, Friedemann SchadAbstractIntroductionViscum album L. extracts (VA) are frequently used in integrative oncology to enhance health-related quality of life. As a central aspect of well-being is associated with feeling warm or cold the internal coherence scale (ICS) questionnaire including the thermo coherence measurement was utilized.MethodsA prospective observational longitudinal cohort study was conducted, using data from the Network Oncology clinica...
Source: European Journal of Integrative Medicine - Category: Complementary Medicine Source Type: research
Understanding the tumor immune microenvironment (TIME) promises to be key for optimal cancer therapy, especially in triple-negative breast cancer (TNBC). Integrating spatial resolution of immune cells with laser capture microdissection gene expression profiles, we defined distinct TIME stratification in TNBC, with implications for current therapies including immune checkpoint blockade. TNBCs with an immunoreactive microenvironment exhibited tumoral infiltration of granzyme B+CD8+ T cells (GzmB+CD8+ T cells), a type 1 IFN signature, and elevated expression of multiple immune inhibitory molecules including indoleamine 2,3-di...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
ConclusionThe combined regimen of the proteasome inhibitor delanzomib with Dox chemotherapy may become an effective strategy for breast cancer therapy.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
In this study, pegylated (stealth) liposomes conjugated to human serum albumin (HSA) were investigated for the delivery of a model drug (calcein) to breast cancer cells. The fluorescent results showed that calcein uptake by the two breast cancer cell lines (MDA-MB-231 and MCF-7) was significantly higher with the HSA-PEG liposomes compared to the non-targeted control liposomes. Furthermore, the exposure to low-frequency ultrasound (LFUS) resulted in a statistically significant uptake of calcein compared to the uptake without ultrasound. The described drug delivery (DD) system, which involves combining the targeted liposomal...
Source: Artificial Cells, Nanomedicine and Biotechnology - Category: Biotechnology Tags: Artif Cells Nanomed Biotechnol Source Type: research
Authors: Zhao L, Zhou S, Gustafsson JÅ Abstract Nuclear receptors (NRs) are transcription factors actively involved in many aspects of human physiology and pathology, serving as sensors of stimuli, master regulators of downstream molecular events and hubs governing complex gene regulatory networks. The importance of various members of the NR superfamily in cancer has led to substantial efforts to target them therapeutically. Notably, drugs that block the action of estrogen receptor alpha (ERα) in patients with ERα+ breast cancer or the androgen receptor (AR) in prostate cancer patients have provid...
Source: Endocrine Reviews - Category: Endocrinology Tags: Endocr Rev Source Type: research
ConclusionsThe results show that the psychological intervention group is efficient to improve emotional state and quality of life of women with breast cancer.ResumenAntecedentes/ObjetivoEl cáncer de mama provoca niveles altos de ansiedad y depresión, empeorando la calidad de vida (CV) de las pacientes. En numerosos estudios se ha visto que la terapia grupal reduce la depresión y ansiedad además de mejorar la CV. El objetivo de este estudio es analizar la efectividad de la intervención de la terapia grupal en el estado emocional y la CV de mujeres con cáncer de mama localizado al fi...
Source: International Journal of Clinical and Health Psychology - Category: Psychiatry & Psychology Source Type: research
Volume 47, Issue 1, December 2019, Page 705-714 .
Source: Artificial Cells, Blood Substitutes, and Biotechnology - Category: Biotechnology Authors: Source Type: research
Opinion statementBisphosphonates are utilized routinely in breast cancer. In metastatic disease with bone involvement, bisphosphonates prevent or delay skeletal-related events and can improve pain control. Different agents have shown benefit compared with placebo or no treatment. While in unselected patients, comparison between zoledronic acid and pamidronate did not show a significant difference, exploratory analyses showed that in patients with osteolytic lesions or hypercalcemia, zoledronic acid is superior to pamidronate. De-escalating treatment with zoledronic acid from every 4 to every 12  weeks has been shown t...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
(University of Basel) Scientists from the University of Basel and the University Hospital of Basel have deciphered the molecular mechanisms linking breast cancer metastasis with increased stress hormones. In addition, they found that synthetic derivatives of stress hormones, which are frequently used as anti-inflammatory in cancer therapy, decrease the efficacy of chemotherapy. These results come from patient-derived models of breast cancer in mice and may have implications for the treatment of patients with breast cancer, as reported in Nature.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
Al Moustafa Breast cancer is the most frequent cause of cancer-related deaths among women worldwide. It is classified into four major molecular subtypes. Triple-negative breast cancers (TNBCs), a subgroup of breast cancer, are defined by the absence of estrogen and progesterone receptors and the lack of HER-2 expression; this subgroup accounts for ~15% of all breast cancers and exhibits the most aggressive metastatic behavior. Currently, very limited targeted therapies exist for the treatment of patients with TNBCs. On the other hand, it is important to highlight that knowledge of the molecular biology of breast can...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Hematology | Xgeva